Comments on: Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

Comments on: Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis https://insideout.vn/intellia-announces-first-clinical-evidence-from-ongoing-phase-1-study-that-nexiguran-ziclumeran-nex-z-an-in-vivo-crispr-cas9-based-gene-editing-therapy-may-favorably-impact-disease-progression-in/ Inside Out Sat, 16 Nov 2024 16:31:06 +0000 hourly 1 https://wordpress.org/?v=6.7